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OBJECTIVE: To study the immediate and late results obtained from the implantation of vena cava filters in cancer patients with
deep vein thrombosis concomitant with neoplasia.
METHODS: This was a retrospective evaluation of 50 patients with an association of cancer and deep venous thrombosis who
underwent interruption of the inferior vena cava and the insertion of permanent vena cava filters. The indications for the procedure,
filter implantation technique, early and late complications related to the operation, and the clinical evolution were evaluated.
RESULTS: The most frequent indication for filter implantation was the contraindication for full anticoagulant treatment (80%).
The femoral vein was the preferred access route (86% of the patients). There were no complications related to the surgical
procedure. During the follow-up, the following complications were observed: 1 episode of nonfatal pulmonary thromboembolism,
2 cases of occlusion of the inferior vena cava, and 1 case of thrombus retained in the device. Twenty patients (40%) died due to
progression of the neoplasm.
CONCLUSIONS: Interruption of the inferior cava vein using an endoluminal filter is a procedure with a low rate of complications.
It is a safe and efficient measure for preventing pulmonary embolism in cancer patients who have deep vein thrombosis of the
lower limbs.
KEYWORDS: Vena cava filters. Venous thrombosis. Pulmonary embolism. Neoplasms. Vena cava. Inferior.
The relationship between neoplasia and venous throm-
boembolism is well established, either through the presence
of related risk factors (chemotherapy,1,2,3,4,5,6 hormone
therapy,5-7 immobilization,5 implantation of venous cath-
eters,4,8,9,10 extrinsic compression of deep veins 5), or be-
cause of a possible condition of hypercoagulability that has
still not been completely explained.4,6,11
Around 15% of neoplasic patients may present throm-
boembolic phenomena, and these are the second major
cause of death among these patients.12,13 Likewise, it is
known that individuals with venous thrombosis of unknown
cause present a greater incidence of cancer.
It is not rare for patients with deep vein thrombosis
(DVT) associated with cancer to be in a condition in which
full anticoagulant treatment may be contraindicated: condi-
tions most likely associated with this are cerebral metastases,
active tumoral bleeding, thrombocytopenia or pulmonary
thromboembolism, and the need for invasive procedures.
Therefore, when anticoagulant treatment is contraindicated,
the implantation of vena cava filters is necessary.
There has been a progressive increase in the utilization
of vena cava filters. However, the number of articles re-
garding their utilization in cancer patients is still small, es-
pecially within our country.
The objective of the present work was to prospectively
study the results obtained from the implantation and long-
term utilization of vena cava filters in cancer patients.
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METHOD
We retrospectively evaluated 50 patients with some type
of cancer who concomitantly had deep vein thrombosis in
lower limbs and underwent vena cava filter implantation
between January 1998 and January 2004.
Half of the cases were male patients (25 cases). The
age range was from 28 to 89 years (average of 60.3). The
most frequent indication for the procedure was the pres-
ence of DVT associated with some contraindication for full
anticoagulant treatment (40 patients). The other situations
in which the implantation of a vena cava filter was indi-
cated were (i) the occurrence of pulmonary thromboem-
bolism while the appropriate anticoagulant treatment was
being applied (6 cases); (ii) pulmonary thromboembolism
with severe respiratory dysfunction compromising more
than 50% of the pulmonary parenchyma with right oor
without a right ventricular pressure higher than 60 mm Hg
(4 cases). Among all patients undergoing vena cava filter
implantation, the most frequently found cancer types were
colon and prostate cancer [Table 1].
All the procedures were performed in the surgical room
after digital cavography using iodide contrast, with the aid
of radioscopy. Angiography was repeated after releasing the
filter to observe and document whether the device had been
correctly positioned. All but one of the filters were im-
planted in the infrarenal portion of the vena cava. The only
1 implanted above the renal veins, was in a patient who
had thrombosis of the vena cava below the point where the
renal veins emerge.
General anesthesia was used for 26 patients, of whom
16 underwent operations during the same period of
anesthesia, immediately after blocking the inferior vena
cava. In 15 cases, local anesthesia was chosen, associated
with superficial sedation, and for the remaining 9 patients
local anesthesia alone was used.
The access was by venous puncture in all cases. This
was most commonly performed through the femoral vein
contralateral to the limb affected by the thrombosis (43 pa-
tients). For the remaining 7 patients, the access was by
puncture of the internal jugular vein.
The filters used were: LGM-VenaTech® (B-Braun) in
23 cases, Greenfield® (Boston Scientific) in 17 cases, and
TrapEase® (Johnson & Johnson) in 10 cases.
Full anticoagulant treatment using low molecular weight
heparin and vitamin K antagonists was reintroduced as soon
as the contraindication for this ceased to exist.
The follow-up was performed clinically and by means
of imaging examinations, with preference for duplex scan-
ning of the vena cava, every 6 months during 5 years. If
the patients underwent computerized tomography of the
abdomen due to oncological indication and the image of
the vena cava was satisfactory, the ultrasound examination
was not requested.
We analyzed the implantation success rate exclusively
related to the operative procedure, the immediate and late
complications, and also the length of survival during the
follow-up period of up to 60 months.
RESULTS
The implantation of the filter was adequate in all 50
cases, and this was proven by performing control cavography
after releasing the device. There were no immediate com-
plications from the procedure, which could have included
venous perforation, hematomas of the retroperitoneum or
puncture location, pneumothorax, arterial punctures, emboli-
zation, or inadequate positioning of the filter.
In the patients who underwent the procedure, we ob-
served nonfatal pulmonary thromboembolism despite the
presence of the filter in 1 patient, 2 cases of occlusion of
the inferior vena cava, and the presence of a thrombus re-
tained in the filter in 1 patient. There was no late migra-
tion of the filter. During the follow-up period of the study
twenty patients (40% of the total) died. The cause of death
was progression of the neoplasia in all cases. The length
of survival, considering all 50 patients, was from 3 to 1824
days, with a median of 496 days, during the 5 years fol-
low-up period (Figure 1).
DISCUSSION
Since 1944, when Homans14 described the ligature of
Table 1 - Location of the cancer in patients submitted to
vena cava filter implantation
Neoplasia Number of patients
Colon 8
Prostate 7
Breast 5
Ovary 5
Lung 3
Retroperitoneal sarcoma 3
Urinary bladder 3
Stomach 2
Cervix 2
Endometrium 2
Astrocytoma 2
Non-Hodgkin lymphoma 2
Bone 2
Pancreas 1
Larynx 1
Leukemia 1
Liver 1
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the inferior vena cava as prophylaxis for pulmonary em-
bolism, there has been much progress in the techniques for
blocking the vena cava. Techniques have progressed from
extraluminal procedures for vein interruption using plica-
tion and clips15 to the creation of intraluminal filters.16
Over the last few years, a consensus has been building
up in the literature for the indication of the implantation
of an inferior vena cava filter in cases in which anticoagu-
lation treatment is contraindicated, or for patients who had
pulmonary thromboembolism during full anticoagulation
treatment.17,18,19 Recently, however, with the development
of endovascular materials and techniques, there has been
an even greater willingness to indicate this procedure.20,21
Some authors, such as Cohen22 and Calligaro,23 have pro-
posed implantation of such filters as the first-choice method
for oncological patients with DVT. Such proposals have
also been based on studies that have demonstrated that these
patients are at greater risk of hemorrhagic events than non-
oncological patients.24,25 Nevertheless, in these studies, most
of the cases that evolved with bleeding presented an INR
(international normalized ratio) greater than the proposed
therapeutic levels (up to 3.0) at the time when the
hemorrhage occurred. Thus, our understanding is that this
is a very radical stance, and we do not share these authors’
opinion.
Most of the patients who underwent implantation of an
inferior vena cava filter in our sample had a temporary con-
traindication for anticoagulant treatment during the
intraoperative and immediate postoperative periods. Once
the risk of bleeding secondary to the operation had been
reduced, we reintroduced low molecular weight heparin and
subsequently vitamin K antagonists, in spite of the pres-
ence of the filter. Other situations in which we indicated
the procedure were when pulmonary thromboembolism
occurred during full anticoagulant treatment and when it
greatly affected pulmonary function. In this latter situation,
a new episode of embolism could be fatal, even if the em-
bolus were small. These indications are compatible with
those used in other centers, according a number of re-
ports.16,17,18,19
We believe that oncological patients should be followed
even more closely with regard to anticoagulation control,
since they often present clinical conditions that may inter-
fere with the action of the anticoagulant. However, we be-
lieve that anticoagulant treatment using low molecular
weight heparin or, whenever possible, vitamin K antago-
nists should be the first choice in treating such patients.
The aim would be not only to reduce the risk of pulmo-
nary embolism, but also to have a lower repercussion from
the venous thrombosis for the affected limb. We reserve the
implantation of a vena cava filter for individuals who are
unable to receive any type of anticoagulant drug.
The blocking of the inferior vena cava using an intra-
luminal filter was successfully performed in all the patients.
There were no large- or small-scale complications, and this
is in keeping with the findings from other published se-
ries.19,26,27,28
The high rate of patient handling under general
anesthesia was due to the fact that, in 16 cases, the im-
plantation of the filter was on the same occasion as a large-
scale operation necessarily conducted under this type of
anesthesia. When the blocking of the inferior vena cava was
independently performed, local anesthesia concomitant
with light sedation was preferred, so as to decrease the scale
of anesthesia without causing discomfort to the patient.
Only when sedation was not possible (non-observance of
8 hours of fasting, or poor clinical condition) did we use
local anesthesia alone; in these cases, infiltration of 2%
lidocaine at the puncture location was employed. Wilson
et al 21 also used local anesthesia for the implantation of
vena cava filters for prophylaxis of pulmonary embolism
in patients who had suffered a traumatic spinal cord lesion.
There is no consensus in the literature regarding which
route is most suitable for implanting the vena cava filter.
Some authors have advocated puncture of the internal jugu-
lar vein,17,29,30 while others have preferred puncture of the
femoral vein.28 In the majority of our cases (86%), we per-
formed the procedure by puncture of the femoral vein con-
tralateral to the limb affected by the DVT, with the aim of
avoiding the risks associated with puncture of the subcla-
vian or jugular vein (hemopneumothorax and cervical
hematoma). At the time of writing, we are also perform-
ing the procedure by puncture of the internal jugular vein,
using smaller caliber (6 Fr) insertion devices, if central ve-
nous access is required for the patient. In such cases, the
catheter is positioned before removing the insertion device.
After implanting the filter, we performed a clinical and
Figure 1 - Primary patency results
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radiological follow-up using duplex scanning of the vena
cava every 6 months. The exception to this occurred when-
ever a patient underwent computerized tomography of the
abdomen due to an oncological indication, provided that
such examination gave an adequate image of the vena cava,
thus allowing us to verify the position of the device and
the patency of the vessel.
There is no defined standard for following up patients
with implanted vena cava filters. Such a follow-up can be
performed clinically, or with the aid of imaging examina-
tions, such as a simple radiography of the abdomen, or du-
plex scanning.16,31,32
When the factor that gave rise to the contraindication
for full anticoagulant treatment had been overcome, we re-
introduced anticoagulant drugs (low molecular weight
heparin and/or warfarin), in spite of the presence of the fil-
ter. We believe that this leads to lower rates of rethrombosis,
thrombosis of the vena cava, or pulmonary embolism, and
this is corroborated in the literature.17,27
In our sample, we documented 1 case (0.5%) of symp-
tomatic pulmonary thromboembolism. This is a lower rate
than reported from other centers, where the rate has ranged
from 2.5% to 33%.16,17,19,27,30,33 We also recorded 1 patient
(0.5%) with thrombus retained in the filter and 2 patients
(1%) with thrombosis of the inferior vena cava. These rates
are much lower than found in some series: 10% to 22%
and 7% to 24%, respectively.19,27,30,33 It should be borne in
mind that occlusion of the inferior vena cava could be con-
sidered to be a complication, possibly due to the presence
of the foreign body in the lumen of the vessel, but it may
also signify therapeutic success (retention of the thrombus),
independent of whether the thrombus has a central or mar-
ginal position. No filter migrated in our patients, while such
an occurrence may be found at a rate of more than 20%,
in other reports.27,30
The large number of patients who died can be explained
by considering the fact that our sample consisted of patients
with cancer that were mostly at an advanced stage, and thus
these were individuals with a low life expectancy. It is em-
phasized that none of the 20 deaths could be attributed to
the procedure of implanting the filter or to being a conse-
quence of pulmonary thromboembolism, therefore show-
ing the efficacy of the method. Schleich et al,34 in a pro-
spective follow-up study of 100 patients who had under-
gone implantation of an inferior vena cava filter, also ob-
served that the mortality was greater among those with can-
cer.
CONCLUSION
Implantation of an inferior vena cava filter by an
endoluminal route was shown to be a safe and efficient
method for preventing pulmonary embolism in cancer pa-
tients with DVT.
RESUMO
Zerati AE, Wolosker N, Yazbek G, Nishinari K, Langer M.
Filtros de veia cava inferior em pacientes com câncer:
experiência em 50 casos. Clinics. 2005;60(5):361-6.
OBJETIVO: Estudar os resultados imediatos e tardios obtidos
com a implantação de filtros de veia cava inferior em pacientes
com trombose venosa profunda concomitante a neoplasia.
MÉTODOS: Avaliamos retrospectivamente 50 pacientes
com câncer e trombose venosa profunda associada
submetidos a interrupção de veia cava inferior com filtros
intraluminais definitivos. Foram estudados aspectos
referentes à indicação do procedimento, à técnica de
implante dos dispositivos, complicações precoces e tardias
relacionadas à operação e à evolução dos pacientes.
RESULTADOS: A indicação mais freqüente para o
procedimento foi a impossibilidade de anticoagulação plena
(80% ) e a via de acesso preferencial foi a punção da veia
femoral, realizada em 86% dos pacientes. Não houve
complicações relativas ao implante dos filtros. Durante a
evolução ocorreram: um episódio de tromboembolia
pulmonar não fatal e dois casos de oclusão da veia cava
inferior; em um paciente foi demonstrada a presença de
coágulo retido no dispositivo. Vinte pacientes (40%)
faleceram devido à neoplasia.
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CONCLUSÃO: A interrupção da veia cava inferior com
filtro endoluminal é um procedimento com baixo índice de
complicações e eficaz na prevenção da embolia pulmonar
nos pacientes com tromobose venosa profunda de membros
inferiores portadores de câncer.
UNITERMOS: Filtros de veia cava. Trombose venosa.
Embolia pulmonar. Neoplasias. Veia cava inferior.
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